Cardinal Health (CAH) Laps the Stock Market: Here's Why

Cardinal Health (CAH) recently outperformed the broader market, with shares closing up 1.72% at $161.89 and gaining 6.85% over a prior period, surpassing the S&P 500 and Medical sector. Investors are anticipating its October 30, 2025 earnings report, for which analysts forecast a 17.55% year-over-year EPS increase to $2.21 and 12.96% revenue growth to $59.05 billion. Full-year estimates also project robust growth in both metrics. While the Zacks Consensus EPS estimate saw a slight 0.02% downward revision recently, CAH maintains a Zacks Rank #3 (Hold) and trades at a Forward P/E of 16.85, a premium to its industry, yet its PEG ratio of 1.35 is below the industry average, suggesting potentially favorable growth-adjusted valuation.

Analysis

Cardinal Health (CAH) has demonstrated robust market performance, with shares closing up +1.72% at $161.89, significantly outpacing the S&P 500's 0.79% gain. Over a prior period, CAH shares advanced 6.85%, surpassing both the Medical sector's 3.99% and the S&P 500's 1.27%, indicating strong relative strength.

The company is scheduled to release earnings on October 30, 2025, with consensus estimates projecting a 17.55% year-over-year EPS increase to $2.21 and 12.96% revenue growth to $59.05 billion for the quarter. Full-year forecasts also anticipate strong growth, with EPS expected to rise 14.68% to $9.45 and revenue by 11.87% to $249 billion.

Despite these positive growth projections, the Zacks Consensus EPS estimate saw a slight 0.02% downward revision over the past month, contributing to CAH's current Zacks Rank #3 (Hold). In terms of valuation, CAH trades at a Forward P/E of 16.85, a premium to its industry average of 13.51, yet its PEG ratio of 1.35 is below the industry's 1.64, suggesting a more attractive growth-adjusted valuation within the top 40% ranked Medical - Dental Supplies industry.

Key Decisions for Investors

• Investors should monitor Cardinal Health's upcoming October 30, 2025 earnings report for confirmation of projected double-digit EPS and revenue growth, which could impact short-term price action.
• Evaluate CAH's valuation, considering its premium Forward P/E of 16.85 against the industry average of 13.51, but also its more favorable PEG ratio of 1.35 compared to the industry's 1.64.
• Acknowledge the recent slight downward revision in EPS estimates and the Zacks Rank #3 (Hold) as potential signals for a neutral near-term outlook, despite the company's strong industry positioning.